Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangxi Rimag Group CoFRA:RD9 +3.42%14 EBIT per Share is €0.01 as of Dec. 2025. GuruFocus rates FRA:RD9 with a GF Score™ of 14/100. The stock has 6 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Jiangxi Rimag Group Co ranks worse than 64.24% on this metric.
Jiangxi Rimag Group Co's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Jiangxi Rimag Group Co's EBIT per Share or its related term are showing as below:
FRA:RD9'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 3.1 Med: 33.9 Max: 64.7
Current: 3.1
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Jiangxi Rimag Group Co was 64.70% per year. The lowest was 3.10% per year. And the median was 33.90% per year.
FRA:RD9's 3-Year EBIT Growth Rate is ranked worse than 64.24% of 523
companies
in the Healthcare Providers & Services industry
Industry Median: 11.9
vs FRA:RD9: 3.10
Jiangxi Rimag Group Co (FRA:RD9) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Jiangxi Rimag Group Co EBIT per Share Related Terms
Jiangxi Rimag Group Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Jiangxi Rimag Group Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Rimag Group Co (FRA:RD9) has a EBIT per Share of €0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jiangxi Rimag Group Co and its competitors. According to the industry distribution chart, Jiangxi Rimag Group Co ranks #336 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 64.2%.
Is Jiangxi Rimag Group Co's EBIT per Share too high?
Jiangxi Rimag Group Co's current EBIT per Share is €0.01. Based on the distribution chart, Jiangxi Rimag Group Co ranks #336 out of 523 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Jiangxi Rimag Group Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Rimag Group Co's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jiangxi Rimag Group Co ranks #336 out of 523 companies for EBIT per Share. This places Jiangxi Rimag Group Co in the lower half of its industry. The industry median EBIT per Share is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jiangxi Rimag Group Co and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Rimag Group Co's current EBIT per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Rimag Group Co stock overvalued right now?
Jiangxi Rimag Group Co (FRA:RD9) has a current EBIT per Share of €0.01. The current EBIT per Share is €0.01. Jiangxi Rimag Group Co's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Jiangxi Rimag Group Co (FRA:RD9), the current EBIT per Share is €0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Rimag Group Co Ltd is a medical group specializing in medical imaging in China. The company generates revenue through these segments: Imaging Center Services, Imaging Solution Services, and Digital-intelligence services. The Imaging Center Services include examination and diagnostic services to patients and other healthcare consumers via its flagship imaging centers, such as MRI, CT, PET, X-ray, ultrasound and mammography. Majority of the revenue comes from Imaging center services. Geographically, the company operates in Chinese Mainland and Overseas (including Hong Kong and Macau). It generates maximum revenue from Chinese Mainland.
14GF Score
Get the complete analysis for FRA:RD9
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RD9 has been successfully added to your 
